Profhilo and dermal fillers, how they differ

Both sit on the injectable tray, both use hyaluronic acid, but only one is intended to add volume.

Clients frequently arrive requesting Profhilo by name, having read about it online or heard about it from a friend. In clinical practice, however, the right product for their concern is often a cross-linked hyaluronic acid filler rather than a bio-remodelling agent. The two product categories share an active ingredient but differ fundamentally in molecular architecture, mechanism of action, indication, and technique. This article provides a side-by-side clinical reference to support accurate product selection and informed practitioner-client discussion.

What is Profhilo?

Profhilo (IBSA Institut Biochimique SA) is a patented injectable formulation containing 64 mg of hyaluronic acid per 2 ml syringe, comprising equal concentrations of high-molecular-weight (H-HA) and low-molecular-weight (L-HA) HA. The product uses a thermal process (NAHYCO technology) rather than chemical cross-linking agents to stabilise the two HA chains in a hybrid cooperative complex. This means there is no BDDE (1,4-butanediol diglycidyl ether) or similar cross-linker present, and the HA remains highly biocompatible.

Once injected, Profhilo disperses widely through the dermis and subcutis rather than staying localised. It acts primarily as a bio-remodeller: stimulating fibroblast activity, improving dermal hydration, and supporting the production of collagen types I and IV and elastin, as described in peer-reviewed literature (see PMC8211329). The result is improvement in skin quality, laxity, and hydration over a course of two sessions, four weeks apart, rather than any measurable volume gain.

IBSA has also introduced Profhilo Structura, a higher-viscosity formulation designed for subdermal placement to address mild tissue laxity in areas such as the cheek and inner arm, though it remains distinct from a volumising filler in both its mechanism and its positioning in the product range.

What are cross-linked HA dermal fillers?

Conventional dermal fillers are manufactured by cross-linking HA chains using BDDE or similar agents, producing a cohesive gel with defined rheological properties (G-prime, viscosity, cohesivity). The degree of cross-linking and the HA concentration determine how stiff, how spreadable, and how long-lasting the product is.

Unlike Profhilo, cross-linked HA fillers are designed to stay where they are placed, occupying space and providing structural support or volume. Product families such as Restylane Skinboosters sit at the softer, more hydrating end of the cross-linked spectrum, while higher G-prime products are intended for deep structural work including malar augmentation, chin projection, and jawline definition. The cohesive gel resists deformation under the mechanical forces of facial expression and movement.

Because they contain a chemical cross-linker, most cross-linked HA fillers are reversible with hyaluronidase, a consideration that is relevant to both complication management and planned product removal. The CMAC guideline on hyaluronic acid and vascular occlusion provides the current standard reference for vascular occlusion management, including hyaluronidase dosing protocols.

Mechanism and molecular architecture: the key distinction

The clinical difference between the two categories starts at the molecular level. Profhilo contains un-cross-linked HA stabilised by thermal bonding. It has a very high HA concentration (64 mg/2 ml) but no added cross-linker, so it integrates rapidly into tissue, spreads widely, and does not create a localised depot. Its primary action is biological: it activates receptors on fibroblasts and keratinocytes, supporting endogenous matrix production.

Cross-linked HA fillers contain chemically stabilised HA that resists enzymatic degradation and mechanical displacement. They are designed to persist in a defined location, occupying volume or lifting tissue by physical means. The bio-remodelling effect that Profhilo produces is not a primary goal of cross-linked fillers, though some incidental fibroblast stimulation may occur around any HA injection.

This distinction matters in practice because a practitioner who uses Profhilo expecting volume gain will disappoint the client, and one who uses a structural filler where skin quality improvement is the goal will over-treat the tissue with material that is harder to remove and potentially inappropriate for the depth of concern.

Indications: choosing the right product

Profhilo is indicated for skin quality concerns: crepey or lax skin texture, loss of dermal hydration and elasticity, and early signs of intrinsic ageing where the skin surface rather than the facial architecture is the primary issue. It is frequently used on the face, neck, decolletage, hands, and inner arms. It is not appropriate where volume loss or structural support is needed.

Cross-linked HA fillers are indicated for volumisation and structural correction: restoring malar volume, defining the jawline, projecting the chin, filling nasolabial folds, augmenting lips, and repositioning tissue that has descended due to volume loss and ligamentous laxity. Softer products at the lower end of the G-prime range, including skin boosters such as Restylane Skinboosters and Sunekos (which contains amino acids alongside non-cross-linked HA), occupy an intermediate position and are often used for perioral fine lines, periorbital crepiness, and hand rejuvenation, where some hydration and mild volumisation are both desirable.

In many clients, the correct treatment plan uses both categories concurrently or in sequence. Profhilo improves the quality of the skin envelope while a structural filler restores the underlying architecture. These are complementary rather than competing approaches.

Injection technique and anatomical considerations

Profhilo on the face is typically delivered using the five-point BAP (Bio Aesthetic Points) technique, injecting 0.2 ml boluses at predetermined anatomical landmarks in each hemi-face to achieve even distribution. The product diffuses from these points, so precise micro-droplet placement as used with some fillers is not required. The injection is generally superficial to deep dermis or immediate subdermal, and the product spreads naturally through tissue planes.

Cross-linked HA fillers require technique matched to the product and the target plane. Deep structural fillers are placed supraperiosteal or in the deep fat compartments. Intermediate products go into the mid to deep dermis or subcutaneous layer depending on indication. Superficial placement of a high G-prime product risks visible nodularity and the Tyndall effect. Practitioners must select both the correct product and the correct depth for every injection point, and should be competent in vascular anatomy relevant to each area treated.

Vascular occlusion risk exists with cross-linked HA fillers placed near named vessels (angular, supratrochlear, infraorbital, labial). The CMAC guideline referenced above sets out the recommended emergency protocol. Profhilo, injected at the BAP points and in superficial planes, carries a lower vascular risk profile, though no injectable procedure in the face is entirely without risk. The British College of Aesthetic Medicine guidance on dermal fillers provides a relevant framework for practitioner standards across both product categories.

Side-by-side comparison

Selecting the right option for your client

A structured assessment approach helps avoid product misallocation. Consider the following questions before product selection:

• Is the primary concern skin quality (texture, hydration, laxity of the skin surface) or structural volume loss?
• Does the client need lifting or support of a tissue compartment, or improvement of the overlying skin?
• Is the client seeking an outcome that requires staying power in a defined anatomical location, or wide dermal improvement?
• What is the client's history of previous filler placement? Existing product in deeper planes may influence safe placement of further cross-linked material.
• Would a combination approach (bio-remodelling followed by structural filler, or concurrent in different planes) serve the presentation better than a single product?

Practitioners can browse the full product range at Longeva Pharmacy, which stocks both Profhilo and a range of cross-linked HA fillers, to select the appropriate SKU for each clinical scenario.

Key takeaways

• Profhilo and cross-linked HA fillers both use hyaluronic acid but differ fundamentally in molecular structure, mechanism, and clinical purpose.
• Profhilo bio-remodels the dermis and improves skin quality. It does not add volume.
• Cross-linked HA fillers provide structural support and volume. They remain localised at the injection site.
• The BAP technique is specific to Profhilo. Cross-linked fillers require technique and depth matched to the product and the anatomical target.
• Vascular occlusion risk is present with any injectable; practitioners should be familiar with the CMAC hyaluronidase protocol for HA fillers.
• Many clients benefit from a planned combination approach. The two categories are complementary, not interchangeable.
• Always base product selection on a structured clinical assessment, not on the client's stated product preference.

References

• IBSA Institut Biochimique SA: Profhilo product information (manufacturer information for Profhilo)
• JCAD / CMAC: Guideline on hyaluronic acid and vascular occlusion management
• PMC8211329: Clinical evidence for HA bio-remodelling agents (PubMed Central)
• British College of Aesthetic Medicine (BCAM): Dermal fillers guidance

Reviewed for clinical accuracy under the supervision of our Superintendent Pharmacist, Alicia Barker (GPhC 2241860). Longeva Pharmacy is a GPhC-registered pharmacy (registration 9012378) operating under MHRA WDA(H) licence 59619. Information is intended for licensed UK practitioners and does not replace individual clinical judgement.